Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Nicotinamide riboside in Idiopathic Pulmonary Fibrosis: NCT06567717 Clinical Landscape Report 2026
28 September 2026
NCT06567717 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TLC-2716 in Hypertriglyceridemia: NCT06564584 Clinical Landscape Report 2026
28 September 2026
NCT06564584 clinical landscape for Hypertriglyceridemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinat FGF21-Fc fusion Protein(Ampsource Biopharma) in Metabolic Dysfunction Associated Steatohepatitis: NCT06569524 Clinical Landscape Report 2026
28 September 2026
NCT06569524 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: NCT06569381 Clinical Landscape Report 2026
28 September 2026
NCT06569381 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Digoxin in Metabolic Dysfunction Associated Steatohepatitis: NCT06588699 Clinical Landscape Report 2026
28 September 2026
NCT06588699 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
CS-060380 in Hyper LDL cholesterolaemia: NCT06573528 Clinical Landscape Report 2026
28 September 2026
NCT06573528 clinical landscape for Hyper LDL cholesterolaemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BI 3804379 in Fibrosis, Liver: NCT06575400 Clinical Landscape Report 2026
28 September 2026
NCT06575400 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Denifanstat in Metabolic Dysfunction Associated Steatohepatitis: NCT06594523 Clinical Landscape Report 2026
28 September 2026
NCT06594523 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: NCT06589921 Clinical Landscape Report 2026
28 September 2026
NCT06589921 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CMR-316 in Idiopathic Pulmonary Fibrosis: NCT06589219 Clinical Landscape Report 2026
28 September 2026
NCT06589219 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Buloxibutid in Idiopathic Pulmonary Fibrosis: NCT06588686 Clinical Landscape Report 2026
28 September 2026
NCT06588686 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: NCT06588517 Clinical Landscape Report 2026
28 September 2026
NCT06588517 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.